Best Probiotic for Antibiotic-Associated Diarrhea
For preventing antibiotic-associated diarrhea in both adults and children, use either Lactobacillus rhamnosus GG or Saccharomyces boulardii CNCM I-745, with S. boulardii having the most extensive evidence base across all patient populations and settings. 1, 2, 3
Evidence-Based Strain Selection
First-Line Choices
Saccharomyces boulardii CNCM I-745 is the most extensively studied probiotic for AAD prevention and demonstrates:
- Evidence-based efficacy in all patient groups: outpatients, hospitalized children, and adults 2
- Reduction in AAD risk with low probability of adverse events 1
- Specific dosing: 1 gram containing 3 × 10^10 CFU/day 4
- Superior performance with fewest adverse effects across multiple studies 5
Lactobacillus rhamnosus GG (LGG) represents an equally strong alternative with:
- Highest probability of being ranked best in both effectiveness (OR 0.28,95% CI 0.17-0.47) and tolerance (OR 0.44,95% CI 0.23-0.84) 6
- Strong evidence in children and outpatient adults 2
- Moderate quality of evidence with strong recommendation from European pediatric guidelines 3
- Dosing: 10^11 CFU/day 1
For Clostridium difficile Prevention
When specifically concerned about C. difficile-associated diarrhea:
Primary recommendation: S. boulardii reduces CDAD risk by 64% when given with antibiotics 1
Alternative: Lactobacillus casei shows superior efficacy for C. difficile (OR 0.04,95% CI 0.00-0.77), though with less robust tolerance data 6
The 2020 AGA guidelines suggest specific strain combinations for C. difficile prevention, including:
- 2-strain: L. acidophilus CL1285 + L. casei LBC80R
- 3-strain: L. acidophilus + L. delbrueckii subsp. bulgaricus + Bifidobacterium bifidum
- 4-strain combinations as listed 7
Clinical Algorithm
Step 1: Assess Risk Level
- High-risk factors: hospitalized patients, broad-spectrum antibiotics (especially cephalosporins, β-lactam/enzyme inhibitors, carbapenems), elderly, previous AAD episodes, ICU patients 8
- Standard risk: outpatient antibiotic use
Step 2: Select Probiotic
- For general AAD prevention: Start S. boulardii CNCM I-745 (1g daily) OR LGG (10^11 CFU/day)
- For C. difficile concern: Prioritize S. boulardii
- For younger patients (<53 years): L. acidophilus LA85 shows significant benefit in subgroup analysis 9
Step 3: Timing
- Begin probiotic simultaneously with antibiotic initiation
- Continue throughout antibiotic course plus 5-7 days after completion
Important Caveats
Strain specificity is critical: The effect of probiotics is strain-specific—no general statement can be made about "probiotics" as a class 2. Using unspecified or different strains than those studied will not provide the documented benefits.
Combination products: Despite theoretical appeal, strain combinations have not demonstrated superiority over single strains in either efficacy or tolerability 6. Stick with the proven single strains unless using the specific AGA-recommended combinations for C. difficile.
Setting matters: Most evidence comes from hospitalized patients. Outpatient benefit exists but may be less pronounced, particularly in low-risk scenarios 7.
Immunocompromised patients: Exercise caution in severely immunocompromised or critically ill patients, though serious adverse events remain rare across studies 1, 3.
Dosing Specifics
- S. boulardii: 1 gram (3 × 10^10 CFU) daily
- LGG: 10^11 CFU daily
- L. acidophilus LA85: 2 × 10^9 CFU daily 9
The evidence consistently supports these two strains above all others, with S. boulardii having the broadest applicability across patient populations and clinical settings 5, 2, 10.